Versartis Obtains $21,000,000 Series B Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8014cbf6-b7cd-47b5-ad14-53d1f99f3349&Preview=1
Date
2/16/2011
Company Name
Versartis
Mailing Address
500 Ellis Street Mountain View, CA 94043
Company Description
Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
Website
http://www.versartis.com
Transaction Type
Venture Equity
Transaction Amount
$21,000,000
Transaction Round
Series B
Proceeds Purposes
Versartis plans to use the proceeds primarily to conduct clinical trials of its lead product, VRS-317, for growth hormone deficiency (GHD) in both adult and pediatric patients.
M&A Terms
Venture Investor
New Leaf Venture Partners
Venture Investor
Advent Venture Partners
Venture Investor
Index Ventures
Venture Investor
Undisclosed